Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

Transcription

1 Note: Page numbers of article titles are in boldface type. A Abciximab for acute coronary syndromes, for complication prevention, 522 for endovascular interventions, 630 for STEMI, parenteral, 538, , 543 ACE trial, 538 ACUITY trial, 518, 520, 544, 558, 565, 649 Acute coronary syndromes, non-st segment elevation, antithrombotic therapy for, ACUTE-II trial, 542 ADAPT-DES trial, 592, 609 Adenosine, Adenosine diphosphate in thrombus formation, 501 platelet function testing and, ADMIRAL trial, 540, 543, 655 ADVANCE trial, 541, 543 Aggregometry, AIDA trial, 577 Alteplase, 648 Antiarrhythmic drugs, 667 Anticoagulants for acute coronary syndromes, for STEMI, , 580 for stent placement, mechanism of action of, monitoring of, properties of, reversal of, Antihistamines, for anticoagulant reversal, 645 Antiplatelet agents. See also specific agents. for acute coronary syndromes, 559, for complication prevention, 519, for STEMI, for stent placement, in triple therapy, mechanism of action of, monitoring of, parenteral, pharmacology of, properties of, strategies for, 608 Antithrombotic therapy. See also specific agents. basic principles of, combination Intervent Cardiol Clin 2 (2013) /13/$ see front matter Ó 2013 Elsevier Inc. All rights reserved. after stent placement, duration of, for acute coronary syndromes, for STEMI, complications of, for endovascular interventions, for valvular and structural disease interventions, monitoring of, oral antiplatelets, parenteral, pharmacogenomics of, platelet function testing in, Aortic valve, transcatheter implantation of, Apixaban for stent placement, , 601 mechanism of action of, 508 APPRAISE trials, 508, , 601 ARCTIC trial, 609, 611 ARGAMI trials, 649 Argatroban monitoring of, 650 parenteral, 540, 544, 548 properties of, reversal of, 650 ARG-E04 trial, 649 ARISTOTLE trial, 600 ARMYDA-PROVE study, 533 ASPIRE trial, 547, 648 Aspirin for acute coronary syndromes, 559, for endovascular interventions, 628 for STEMI, 574, for stent placement, 587, 592, , for valvular and structural interventions, 638 mechanism of action of, 502 monitoring of, pharmacology of, properties of, reversal of, 653 Atherosclerosis, antithrombotic therapy action on, ATLAS ACS TIMI trials, 508, 522, 598 Atopaxar, mechanism of action of, 505 Atorvastatin, periprocedural, Atrial fibrillation, Atrial septal defect closure, interventional.theclinics.com

2 672 B Benzodiazepines, for sedation, 667 Beta blockers, for arrhythmias, 667 Bivalvirudin for acute coronary syndromes, for complication prevention, 518, 520 for endovascular interventions, 631 for STEMI, monitoring of, 650 parenteral, 539, 544, properties of, reversal of, 650 Bleeding Academic Research Consortium, 589 Bleeding complications. See Complications, ischemic or bleeding. BRAVE trials, 576, BRIDGE trial, 504, 592 C CADILLAC trial, 538, 543, 655 Calcium channel blockers, Candidate gene studies, for pharmacogenomics, Cangrelor for acute coronary syndromes, for STEMI, 576 for stent placement, 592 mechanism of action of, pharmacology of, CAPRIE trial, 652 CAPTURE trial, 538, 540, 543 CHADS2 score, 702 CHAMPION trials, , 565, 576 Cilostazol for endovascular interventions, 631 for stent placement, , mechanism of action of, 505 CLARITY-TIMI trial, 652 Clopidogrel for acute coronary syndromes, , 569 for complication prevention, for endovascular interventions, for STEMI, , for stent placement, , , 596, 600, 602 for valvular and structural interventions, mechanism of action of, 502 metabolism of, 618 pharmacogenomics of, pharmacology of, platelet function testing and, CLOSURE-1 trial, 639 COMMIT trial, 652 Complications, ischemic or bleeding, definitions of, outcomes of, preventive strategies for, risk assessment for, Contrast agents, discontinuation of, Corticosteroids, for anticoagulant reversal, 645 CPY450 polymorphisms, in pharmacogenomics, CREDO trial, 652 CRUISE trial, 546 CRUSADE trial, 601 CURE trial, 562, 619, 652 D Dabigatran for stent placement, Dalteparin, parenteral, 546 DATE trial, 590 DECREASE trial, 596 Desmopressin for aspirin reversal, 653 for cangrelor reversal, 654 for glycoprotein IIb/IIIa inhibitor reversal, 657 Diltiazem, 666 Dipyridamole for endovascular interventions, 629 mechanism of action of, 505 Direct antithrombin agents, parenteral, Direct factor-xa inhibitors, mechanism of action of, 508 Direct thrombin inhibitors, mechanism of action of, 507 Diuretics, discontinuation of, 668 Dual antiplatelet therapy for stent implantation, addition to for triple therapy, cessation of, long-term outcomes of, perioperative management in, practice guidelines for, short-term outcomes of, ultrasound guidance for, 591 for valvular and structural interventions, 638 platelet function testing in, Dual therapy, for acute coronary syndromes, non-st segment elevation, DX9065a, mechanism of action of, 508 E ELECT trial, 647 ELEVATE-TIMI trial, 609, 620 Elinogrel

3 673 pharmacology of, 532 ENDOMAX trial, 631 Endovascular interventions, antithrombotic agents for, pathophysiology of, types of, ENGAGE-AF trial, 600 Enoxaparin for acute coronary syndromes, , 568 for complication prevention, 518 for STEMI, 580 monitoring of, parenteral, 539, 542, 546 properties of, reversal of, 647 EPIC trial, 538, 540, 543, 655 Epifibtide, parenteral, 538, 541 EPILOG trial, 538, 540, 543, EPISTENT trial, 538, , 543, 655 Eptifibatide for acute coronary syndromes, for complication prevention, 522 for STEMI, 577 parenteral, 543 ESPRIT trial, 538, 541, 543, 656 ESPS trial, 505 ESSENCE/TIMI-11B trial, 542, 646 EUCLID trial, 629 EVEREST trial, 636, 639 Everolimus-coated stents, EXCELLENT trial, Exome sequencing, in pharmacogenomics, 617 ExTRACT-TIMI trial, 542, 546, 580 F Factor VIIa, recombinant, for anticoagulant reversal, 648, 650 Factor-XA inhibitors, mechanism of action of, Fentanyl, for sedation, 667 Fibrin, in thrombus formation, 501 Fibrinolysis, PCI after, FINESSE trial, Fondaparinux for acute coronary syndromes, , 568 for complication prevention, 518 for STEMI, monitoring of, 648 parenteral, 540, 544, 547 properties of, reversal of, 648 FRANCE-2 trial, 638 G Genome-wide association studies, in pharmacogenomics, Genomics, for pharmacology. See Pharmacogenomics. GIFT study, 620 Glycoprotein IIb/IIIa inhibitors for acute coronary syndromes, for endovascular interventions, 630 for STEMI, for stent placement, 597, 604 monitoring of, parenteral, properties of, reversal of, 657 GOLD multicenter study, 656 GRACE trial, 516, 518 GRACIA trial, GRAVITAS trial, 609, 611, 620, 654 GUSTO trial, 516 GUSTO trials, 546 Guthrie PCI Registry, 590 H HAS-BLED risk score, 518, 520, 601 HEMONOX assay, 647 Heparins for acute coronary syndromes, for complication prevention, 520 for endovascular interventions, 630 for STEMI, , 580 for valvular and structural interventions, 639 mechanism of action of, monitoring of, 645 parenteral, 539, 542, properties of, reversal of, 645 Hirudin, HMO Research Network Stent registry, 589 HORIZONS-AMI trials, 516, , 544, 548, , 590, 648 Hybridization oligonucleotide capture, in pharmacogenomics, 617 I Idrabiotaparinux, 508 Idraparinux, 508 IMPACT trials, 538, 541, 655 Impact-F assay, 652 INFUSE-AMI trial, INTERACT A to Z trial, 542 Intravascular ultrasonography, for stent implantation, 591 ISAR trials, 538, 543

4 674 ISAR-REACT trials, 538, 541, , 548, 649 Ischemic complications. See Complications, ischemic or bleeding. ISR-SAFE trial, 591 K Kidney, drugs toxic to, L LANCELOT trials, 505 Lepirudin parenteral, 548 Lidocaine, for arrhythmias, 667 Light remittance aggregometry, , 656 M MATRIX trial, 592 Mean platelet volume, in antiplatelet therapy, 533 Metformin, discontinuation of, 668 Midazolam, for sedation, 667 MitraClip, Mitral valve repair, Mortality, in antithrombotic therapy complications, MULTISTRATEGY trial, 576 Myocardial infarction definition of, 516 ST segment elevation (STEMI), primary percutaneous coronary intervention for, rescue percutaneous coronary intervention for, N NICE-1 registry, 546 NICE trials, 646 Nitroglycerin, Nonsteroidal anti-inflammatory drugs, discontinuation of, 668 No-reflow phenomenon, vasodilators for, 666 O OASIS trials, 519, 544, 547, , 580, 648 Opioids, for sedation, 667 Oral anticoagulants, for stent placement, Otamixaban, mechanism of action of, 508 P Paclitaxel-coated stents, PAR-1 inhibitors, mechanism of action of, 505 PARIS trial, 592 PARTNER trial, 636 Patent foramen ovale closure, PCI. See Percutaneous intervention. PENTUA trial, 544, 648 Percutaneous intervention primary, antithrombotic therapy for, rescue, antithrombotic therapy for, Personalized therapy pharmacogenomics for, platelet function testing for, PFA-100 assay, 652 Pharmacogenomics, basic principles of, of clopidogrel, of ticagrelor, 621 Phosphodiesterase inhibitors, mechanism of action of, 505 Platelet(s), in thrombus formation, Platelet concentrate for aspirin reversal, 653 for cangrelor reversal, 654 for glycoprotein IIb/IIIa inhibitor reversal, 657 Platelet function testing, See also individual drugs, monitoring of. bleeding during surgery and, cutoff values in, 609 importance of, in personalized therapy, methods for, 652 therapeutic window concept in, PLATFORM trial, 503 PLATO trial, 503, , , 654 POPULAR trial, 611 Prasugrel for acute coronary syndromes, for complication prevention, for endovascular interventions, 629 for STEMI, , 580 for stent placement, 587, 596 mechanism of action of, pharmacogenomics of, pharmacology of, PREMIER registry, 516 PRISM trials, 541, 656 PRODIGY trials, PRoFESS trial, 505 Propofol, for sedation, 667 Protamine sulfate, for anticoagulant reversal, 645, 647 PURSUIT trial, 656 P2Y12 inhibitors. See also specific agents, eg, Clopidogrel. for acute coronary syndromes, for STEMI, monitoring of, 654 properties of, reversal of, 654

5 675 R RADAR trial, 509 Radial arterial spasm, vasodilators for, RAPPORT trial, 540, 543 REAL-LATE trial, Receiver operating characteristic curve, in platelet function testing, 609 RE-DEEM trial, 507, REG1 system, mechanism of action of, 509 RE-LY trials, REPLACE trials, 518, 520, 544, , RESET trial, 590 RESORT trial, 538 RESPECT trial, RESTORE trial, 541, 656 Rivaroxaban for stent placement, 598 mechanism of action of, 508 RNA aptamer technology, 509 ROCKET-AE trial, 600 Rosuvastatin, periprocedural, S SCAAR registry, 576 Sedation, periprocedural, 667 Sirolimus-coated stents, Spasm, radial artery, vasodilators for, SR , 508 STACKENOX trial, 646 Statins, periprocedural, STEEPLE trial, , Stents antithrombotic therapy for, 565, 569 dual combination antiplatelet therapy for, duration of, thrombosis of, triple therapy for, STREAM trial, 578 Stroke definition of, 516 in valvular and structural interventions, prevention of, Structural heart disorders, interventions for, SYNERGY trial, 542, 546, 555, 646 T TARGET trial, 541, , 656 TAVI (transcatheter aortic valve implantation), TENACITY trial, 541, 545 Tenecteplase, for STEMI, Terutroban, mechanism of action of, 506 Therapeutic window, in platelet function testing, Thienopyridines, pharmacology of, Thrombin, in thrombus formation, 502 Thrombin inhibitors, mechanism of action of, Thromboelastography, 652 Thrombosis in valvular and structural interventions, prevention of, pathophysiology of, 596, stent, Thromboxane, in thrombus formation, 501 Thromboxane inhibitors, mechanism of action of, Thrombus, formation of, Ticagrelor for acute coronary syndromes, , 568 for complication prevention, for endovascular interventions, 629 for STEMI, for stent placement, 502, mechanism of action of, 503 pharmacogenomics of, 621 pharmacology of, 531 Ticlopidine, pharmacology of, TIMI risk score, 518 TIMI trial, 591 Tirofiban for acute coronary syndromes, for complication prevention, 522 for STEMI, 577 parenteral, 538, 543 Tissue factor, in thrombus formation, 501 TOPSTAR trial, 541 TRA 2P-TIMI trial, 505 TRACER trial, 505 Transcatheter aortic valve implantation (TAVI), TRANSFER-AMI trial, TRIGGER-PCI trial, 609, 611 TRILOGY-ACS trial, 503 Triple therapy for acute coronary syndrome, 569 for stent placement, TRITON-TIMI trial, , 521, 561, 575, 580, 654 U Ultrasonography, intravascular, for stent implantation, 591 Urokinase, for endovascular interventions, 630 V Valvular diseases, interventions for, Varoxaban, for complication prevention, 522 Vasodilators,

6 676 Vasodilators-stimulated phosphoprotein phosphorylation analysis, 621 Vasospasm, vasodilators for, Verapamil, VerifyNow Assay, , , Vorapaxar, mechanism of action of, 505 for endovascular interventions, for stent placement, 597, WEST trial, Whole exome sequencing, in pharmacogenomics, 617 WOEST trial, 569, 601 W Warfarin for acute coronary syndromes, 569 Z ZEST-LATE trial, Zotarolimus-coated stents,